HCPLive

Hepatitis C 
The MD Magazine Hepatitis C condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

Bristol-Myers Squibb Gets Expanded Use for Hepatitis C Drug in Europe
The European Commission has approved expanded use of a Bristol-Myers Squibb hepatitis C drug to include patient populations with decompensated cirrhosis, HIV-1 coinfection and post-liver transplant recurrence of the virus.
The Centers for Disease Control and Prevention (CDC) is urging dialysis providers to assess and improve infection control practices, in part because the agency has received an increased number of reports of newly acquired HCV infection among patients undergoing hemodialysis.
Merck's Zepatier is a once-daily pill prescribed over 12 or 16 weeks and is approved for treating patients with hepatitis C genotype-1 and genotype-4.
The CDC has seen a tremendous growth in acute HCV infection reports among patients undergoing hemodialysis.
Patients with chronic hepatitis C can develop cirrhosis, a serious condition characterized by scarring of the liver – but just how many patients actually reach this point?
Vertical transmission, or the spread of infection from mother to baby during childbirth, is the most common way that children get hepatitis C. However, it turns out that these children are rarely tested for the disease.
A multi-study analysis shows that a majority of patients with hepatitis C maintained sustained virological response five years after they were treated but researchers found higher risk of reinfection among patients in two subgroups.
Community health centers screen less than 10% of baby boomer patients (and more men than women) for hepatitis C, a much lower percentage than recommended by national guidelines revised in 2013, according to a recently published study.
Even with direct-acting antivirals, not all patients with chronic hepatitis C can be cured. That might be because patients develop antibodies to interferon, a drug that is still part of DAA regimens, Italian researchers report.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$